Residency · Residency · Medical Genetics Genomics
Direct-to-Consumer Genetic Testing: Clinical Implications
Introduction
Direct-to-consumer (DTC) genetic testing allows individuals to order genetic tests without a healthcare provider intermediary. Companies such as 23andMe, AncestryDNA, and others have brought genetic testing to millions of consumers, creating both opportunities and challenges for the clinical genetics community. As DTC results increasingly arrive in clinical encounters, understanding their capabilities, limitations, and appropriate management is essential for all clinicians.
DTC Testing Landscape
Market Overview
Over 40 million people have undergone DTC genetic testing globally. Major companies include 23andMe offering both health and ancestry reports, AncestryDNA focused primarily on ancestry, and newer entrants such as Color Health, Nebula Genomics, and Dante Labs. Tests range from SNP genotyping arrays costing approximately $100-200 to whole genome sequencing at approximately $300-1,000. The FDA has authorized 23andMe to report on select health risk and carrier status variants, lending a degree of regulatory legitimacy that may influence consumer perceptions of clinical validity.
Types of DTC Tests
The DTC market encompasses several categories. Ancestry and genealogy tests provide ethnicity estimates, relative matching, and haplogroup analysis. Health risk reports cover selected variants associated with disease risk, such as BRCA1/2 founder mutations, APOE for Alzheimer disease risk, and LRRK2/GBA for Parkinson disease. Carrier status reports test limited variants for conditions such as cystic fibrosis, sickle cell disease, and Tay-Sachs disease. Pharmacogenomic reports cover CYP2C19, CYP2D6, and other pharmacogenes with limited variant coverage. Trait and wellness reports address non-medical characteristics like caffeine metabolism, earwax type, and muscle composition. Many companies also offer raw data download, allowing consumers to upload their data to third-party interpretation services.
| Feature | DTC Genetic Testing | Clinical Genetic Testing |
|---|---|---|
| Technology | SNP genotyping array (~600K–700K variants) | Gene sequencing, panels, exome, or genome |
| Coverage | Predefined variants only | Comprehensive gene coverage |
| Variant detection | Only pre-selected SNPs; no novel variants | Detects novel, rare, and structural variants |
| Confirmation | No Sanger confirmation | Sanger confirmation for reportable variants |
| Laboratory standard | CLIA (variable rigor) | CLIA-certified with clinical validation |
| Interpretation | Automated; limited clinical context | Expert interpretation with ACMG framework |
| Genetic counseling | Minimal or none | Pre- and post-test counseling standard |
| Regulatory oversight | FDA authorized for select reports | Full clinical laboratory regulation |
| Example: BRCA1/2 | 3 Ashkenazi founder mutations only | Full gene sequencing + del/dup analysis |
| False positive rate (raw data) | 15–40% for third-party tools | <1% for validated clinical assays |
Technology Platform
Most DTC tests use SNP genotyping arrays that interrogate approximately 600,000-700,000 predefined variants. This technology is fundamentally different from clinical-grade sequencing used for gene panels, exome, or genome analysis. SNP arrays detect only the specific variants on the chip and do not comprehensively sequence genes. They cannot detect rare or novel variants, structural variants, or repeat expansions. This distinction is critical for understanding why DTC results cannot substitute for clinical genetic testing.
Clinical Limitations
Incomplete Gene Coverage
The 23andMe BRCA1/2 report tests for only 3 Ashkenazi Jewish founder mutations out of thousands of known pathogenic variants in these genes. A "negative" DTC BRCA1/2 result does not rule out hereditary breast/ovarian cancer. Similarly, carrier screening covers limited variants per gene, whereas clinical carrier screening panels test comprehensively. Pharmacogenomic reports may miss important alleles such as CYP2D6 structural variants and rare star alleles that significantly affect drug metabolism phenotype assignment.
Analytical Limitations
SNP genotyping has a small but non-negligible error rate, with both false positives and false negatives occurring. No Sanger confirmation is performed on DTC results, unlike standard clinical laboratory practice. FDA analysis has found that raw DTC data has a false positive rate of approximately 15-40% for certain clinically relevant variants when analyzed by third-party tools. Imputation, which infers ungenotyped variants from surrounding SNPs, introduces additional uncertainty into results that extend beyond the directly genotyped variants.
Interpretive Limitations
Risk estimates are often based on GWAS with small effect sizes and may not be clinically meaningful for individual patients. Polygenic risk scores from DTC sources are typically not clinically validated for use in medical decision-making. Results are often presented without adequate context regarding penetrance, expressivity, and population-specific risk. Ancestry-related results use reference panels that may not accurately reflect all populations, particularly those with complex admixture patterns.
Clinical Scenarios
Patient Brings DTC Results to Clinical Encounter
Clinicians should not dismiss the patient's results or concerns but rather engage constructively. The specific variant(s) reported and the platform used should be evaluated. The clinician should determine whether the result has clinical validity and clinical utility. For potentially actionable findings such as BRCA1/2 variants or Lynch syndrome genes, confirmatory clinical-grade testing in a CLIA-certified laboratory should be recommended before any clinical action is taken. Referral to genetic counseling for comprehensive interpretation and management planning is appropriate.
False Reassurance Scenario
A patient with a strong family history of breast cancer receives a "negative" DTC BRCA1/2 result. However, the DTC test only evaluated 3 founder mutations, and the family's pathogenic variant is in a different region of BRCA1. The patient is falsely reassured and may forgo recommended clinical genetic testing and cancer screening. This scenario illustrates that a negative DTC result does not replace comprehensive clinical genetic testing when clinically indicated by personal or family history.
Unexpected Findings
DTC testing may reveal non-paternity, unknown siblings, or donor conception through relative-matching features. Unexpected ancestry results can cause identity distress or raise questions about family history. Incidental health findings in genes such as APOE or LRRK2 may cause significant anxiety without clinical context. These findings have no clinical support infrastructure from DTC companies, and patients may present to clinicians needing both medical guidance and psychosocial support.
Regulatory Framework
FDA Oversight
DTC genetic tests marketed for health purposes are regulated as medical devices. The FDA has granted 23andMe authorization for specific genetic health risk reports including BRCA1/2 founder mutations, APOE, and pharmacogenomics. FDA authorization covers the test itself, not clinical decision-making based on the results. Many DTC tests sold for "informational" or "research" purposes operate in a regulatory gray zone. Third-party raw data interpretation tools are largely unregulated and carry no clinical accountability.
Laboratory Standards
Clinical genetic tests must be performed in CLIA-certified laboratories with appropriate quality controls. Most DTC testing laboratories are CLIA-certified but may not follow the same validation standards as clinical diagnostic laboratories. The New York State Department of Health has separate regulatory requirements and has not approved many DTC tests for its residents.
Third-Party Raw Data Interpretation
Consumers can download raw genotyping data and upload it to services such as Promethease, Genetic Genie, LiveWello, and Sequencing.com. These services apply variant annotations from ClinVar, PharmGKB, and other databases to raw data. There is significant risk of misinterpretation because variants may be annotated as pathogenic based on outdated or incorrect database entries. False positive rates are high, and all variants identified through third-party interpretation must be confirmed by clinical testing before any clinical action. There is no quality control or clinical oversight for these third-party services.
Ethical and Social Considerations
Genetic literacy remains low in the general population, and most consumers lack the background to interpret genetic risk information accurately. DTC results can cause anxiety, particularly for non-actionable conditions such as APOE and Alzheimer disease risk. Privacy is a major concern as DTC companies hold massive genetic databases with variable data sharing policies, and law enforcement access to genealogical databases for criminal investigations raises additional privacy questions. Equity remains an issue because DTC reference populations are predominantly of European descent, making results less accurate for other populations. The quality of pre-test information varies substantially across companies, and many consumers do not fully understand what they are consenting to.
Clinical Pearls
DTC genetic testing uses SNP genotyping that interrogates only a fraction of variants in any given gene; a negative DTC result does not exclude clinically significant variants and should never replace indicated clinical testing. All potentially actionable DTC findings must be confirmed by clinical-grade testing in a CLIA-certified laboratory before any clinical management changes are made. Third-party interpretation of raw DTC data carries a high false positive rate and should be treated with extreme caution. Clinicians should engage constructively with patients who bring DTC results, using the encounter as an opportunity for genetic education and appropriate referral to genetic counseling services.
References
- Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genetics in Medicine. 2018;20(12):1515-1521.
- Horton R, Crawford G, Freeman L, et al. Direct-to-consumer genetic testing. BMJ. 2019;367:l5688.
- Grzymski JJ, Elhanan G, Morales Rosado JA, et al. Population genetic screening efficiently identifies carriers of autosomal dominant diseases. Nature Medicine. 2020;26(8):1235-1239.
- Niemiec E, Howard HC. Ethical issues in consumer genome sequencing: use of consumers' genetic data. Science and Engineering Ethics. 2020;26:1411-1434.